Clinical Trials Browser

Advanced Lung Neuroendocrine Tumor

Triple Negative Breast Neoplasms

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

Metastatic Digestive System Neuroendocrine Tumor G1

Neoplasm Metastasis

Breast Neoplasms, Triple Negative Breast Neoplasms

Advanced Breast Cancer

Carcinoma, Renal Cell, von Hippel-Lindau Disease

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Breast Neoplasms

Adenoma, Islet Cell, Neoplasm Metastasis, Neuroendocrine Tumors

Breast Neoplasms

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma

Thymus Neoplasms, Neuroendocrine Tumors

Diffuse Intrinsic Pontine Glioma

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

Breast Neoplasms

Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Gastroenteropancreatic Neuroendocrine Tumors

Neoplasm Metastasis

Glioblastoma, Recurrence

Lymphangioleiomyomatosis

Locally Advanced Thyroid Gland Carcinoma

Carcinoma, Renal Cell, Neoplasm Metastasis

Breast Neoplasms

Gallbladder Neoplasms

Carcinoma, Hepatocellular

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors, Disease Progression

Breast Neoplasms

Carcinoma, Renal Cell, Kidney Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

HR+/HER2- Advanced Breast Cancer

Colorectal Neoplasms

Clinical Trials

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

MOMENTUM-1

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

EVOLVE-BDT

ADELA

MK-6482-043

ACTION-1

LITESPARK-029

STELLAR-311

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

LEVEL

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

BIOMEDE 2

Sapu003 in Advanced mTOR-sensitive Solid Tumors

A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer

GERTRUDE

ESMART

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

ELEVATE

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

LUMEN-1

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

MOST plus

Pilot Trial for Treatment of Recurrent Glioblastoma

ELUMEN

MIDAS

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Addition of Everolimus to Standard of Care in Carcinoma Gallbladder

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

EVENET

BCTOP-L-M01

Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma

BCTOP-T-M03

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

EVIDENT